Biotechnology & therapeutics · Anti-infectives
Matrubials
A UC Davis spin-out turning antimicrobial peptides found in human milk into a topical drug for bacterial vaginosis. Two peer-reviewed papers, one NIH small business grant, a pending patent family, and no clinical trial yet.
A hack, posted at 94 points
On July 30, 2021, a launch post went up on Hacker News under the handle ishishah. It ran four paragraphs of microbiology and closed with a line of salesmanship.
“Converting milk components into therapeutics- now isn’t that a great hack? We think so!”
It drew 94 points and 36 comments, and the founder answered nearly all of them. One reader asked the obvious question: if bacteria learn to beat a milk antibiotic, does that ruin milk for everyone?
“The goal is to dramatically slow down the process of resistance by choice of molecules that are rapid in activity, and creative compositions.”
Another reader worried about supply. Human milk is not a thing you order by the drum.
“Yep. For us, production and scaling is/will continue to be COMPLETELY independent of donor milk.”
That answer matters more than it looks. Matrubials extracts nothing from milk at scale. It reads milk protein sequences, generates peptide candidates computationally, and has the winners made synthetically. Milk is the reference library, not the raw material.
The condition nobody fixed
Bacterial vaginosis is a dysbiosis: the lactobacilli that dominate a healthy vaginal microbiome are displaced by a polymicrobial film of anaerobes led by Gardnerella vaginalis. The CDC calls it “a highly prevalent condition and the most common cause of vaginal discharge worldwide” and links it to higher risk of acquiring HIV, gonorrhea, chlamydia, HPV and HSV-2, plus preterm birth.
The CDC guideline offers metronidazole and clindamycin, both decades old, and says plainly that persistent or recurrent BV is common. The company puts numbers on that: over 50 percent recurrence within six to twelve months on metronidazole, and roughly 70 percent of patients getting repeat infections. It states US prevalence at 21.2 million women aged 14 to 49.
So the target is not an exotic pathogen. It is a common infection with two aging antibiotics and a treatment that flattens the good bacteria along with the bad. Selectivity is the pitch.
Four founders, one institute
Ishita M. Shah is an infectious disease scientist, a senior researcher at Genentech and a postdoc at Columbia before joining the Foods for Health Institute at UC Davis as associate director for microbial programs. Her three co-founders are the institute itself, more or less: J. Bruce German, who directs it and studies the evolution of lactation; David A. Mills, the Peter J. Shields Endowed Chair; and Carlito B. Lebrilla, a distinguished professor of chemistry who built the mass spectrometry methods.
The three professors had already co-founded Evolve Biosystems and BCD Bioscience out of the same milk program. Matrubials is the anti-infective branch of that tree, and Shah is the only full-time operator among the four.
Fractionating milk peptides and spotting them on agar plates against E. coli O157:H7 and Klebsiella pneumoniae came first. The AI step came after, and it is narrow and legible: take dominant milk protein sequences, vary peptide length, charge and predicted structure, and generate thousands of short peptides to screen for killing power and safety.
“We can look through diverse mammalian milks: human, bovine, camel, sheep, goat.”
Grant, patents, papers, prizes
NIAID awarded a Phase I SBIR of $286,968 on May 10, 2022, with Shah as principal investigator. A patent family followed: the application claiming priority to May 18, 2022 published as US20250340592A1 on November 6, 2025, naming Shah as inventor and Matrubials as assignee.
The science reached print in 2026. In March, Pharmaceutics published the bacterial vaginosis work by the four founders. In July, the same journal published an evaluation by CONRAD at Eastern Virginia Medical School, testing three peptides, MAT-006, UCD-MAT-001 and UCD-MAT-002, for mucosal safety and antiviral activity.
The prizes came from Sacramento: the Biopharma category of the 2021 Sacramento Region Innovation Awards, the audience choice award at NorCal AngelCon in November 2025, and a $50,000 prize that December, a second local purse in under a month.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| NIH grant | NIAID SBIR Phase I 1R43AI165105-01A1, $286,968, May 10, 2022 to March 31, 2024. PI Ishita M. Shah. No Phase II award appears in the record. | Public record |
| Paper, BV | Pharmaceutics, March 17, 2026. Computationally designed peptides are bactericidal against Gardnerella vaginalis, spare key lactobacilli, and are safe in EpiVag organoid tissue. All four authors disclose that they co-founded Matrubials. | Public record |
| Paper, antiviral | Pharmaceutics, July 30, 2026, led by CONRAD at Eastern Virginia Medical School. The three peptides inhibited HIV-1 and HSV-2 in cell lines, IC50 0.78 to 7.72 mg/mL, with minimal cytotoxicity in ectocervical explants. Five of six authors report no conflict. | Independent lab |
| Patents | US20250340592A1, priority May 18, 2022, published November 6, 2025, pending. A commercial database lists five publications across the family plus WO-2025111563-A1, on milk peptide compositions for pharmaceutical and cosmeceutical use, filed November 22, 2023. | Public record |
| Clinical trials | No registered trial for Matrubials or its peptides in a records pull on September 22, 2026. | Not found |
| Pre-IND meeting | A November 2025 conference write-up reports a successful pre-IND meeting with the FDA. Such meetings are not public, so no record can confirm it. The company’s February 2026 deck lists IND submission as the next milestone, not a completed one. | Company-stated |
| Animal and ex vivo data | A February 2026 deck describes a 10-day rabbit vaginal irritation assay with “No clinical abnormalities detected during the study” and a 30-patient ex vivo comparison against standard antibiotics on BV swabs. Neither dataset is published. | Company-stated |
| Money raised | The deck shows $1.28M for preclinical work from 2021 to 2025, credited to NIH SBIR, the Gates Foundation, Y Combinator and others. A 2022 profile quoted about $1.1 million raised. Two databases put total funding at $125K to $130K. No Form D is on file. | Figures differ |
| Consumer product | A skin serum, called the company’s first nonmedical product, was reported in December 2025 for release in early 2026. No launch found since. | Independent |
Read plainly: the chemistry is real and now published, including one paper from a laboratory with no stake in the company. Everything downstream of the bench is still ahead. There is no IND, no trial, no dose given in a regulated study, and the capital raised is small even by preclinical standards. The strongest independent signal is the CONRAD paper, because an outside lab tested the peptides and found them safe on cervicovaginal tissue.
What to watch
- An IND filing. The February 2026 deck put it as the next milestone, tied to a 2026 raise of $1.5 million.
- A Phase II SBIR. Phase I ended March 31, 2024 with no follow-on award in the federal record.
- Whether the skin serum ships, and under what brand.
- A Form D, or any filing that reconciles the funding figures. There is none.
- Publication of the rabbit irritation and 30-patient ex vivo data the deck leans on.
In their words
“Converting milk components into therapeutics- now isn’t that a great hack? We think so!”
Ishita Shah, co-founder and CEO, Launch HN post, July 2021 · Founder post
“Yep. For us, production and scaling is/will continue to be COMPLETELY independent of donor milk.”
Ishita Shah, answering a Hacker News commenter, July 2021 · Founder post
“The goal is to dramatically slow down the process of resistance by choice of molecules that are rapid in activity, and creative compositions.”
Ishita Shah, answering a Hacker News commenter, July 2021 · Founder post
“These are very specific components that are present in human milk that have protective effects and can be translated into anti-infective therapeutics that can benefit human health”
Ishita Shah, to Sacramento Business Journal, November 2021 · Independent
“We can look through diverse mammalian milks: human, bovine, camel, sheep, goat.”
Ishita Shah, Comstock’s magazine, August 2022 · Independent
“She is innovating on products that hadn’t been innovated on in 40 years.”
Monique Brown, The Growth Factory, to Comstock’s, August 2022 · Investor
“Lead AMPs from this study offer a promising solution for the development of novel therapeutics for the treatment of BV, which may reduce the burden of AMR.”
Shah, Lebrilla, German and Mills, Pharmaceutics, March 2026 · Peer reviewed
“warranting further preclinical evaluation as microbicide candidates with dual antibacterial and antiviral properties”
Yousefieh and colleagues, CONRAD, Pharmaceutics, July 2026 · Independent lab
Related companies
Sources
- Public recordNIH RePORTER 1R43AI165105-01A1
- Public recordSelective Human-Milk-Inspired Antimicrobial Peptides for the Treatment of Bacterial Vaginosis
- Public recordAntiviral Activity and Mucosal Safety of Novel Human-Milk-Inspired Antimicrobial Peptides
- Public recordUS20250340592A1, Mammalian milk-derived peptides with antimicrobial activity
- Public recordBacterial Vaginosis, STI Treatment Guidelines
- Public recordRecords pull: FDA, trial registries, NIH, NSF, PubMed, SEC
- IndependentSacramento Region Innovation Awards: Matrubials aims to turn a mother’s milk into medicine
- IndependentStartup of the Month: Matrubials
- IndependentDavis-based Matrubials to launch skin care product on parallel track with drug candidate
- IndependentDavis health research company Matrubials wins $50K prize
- IndependentIshita Shah and Matrubials win Sacramento Region Innovation Award
- IndependentMatrubials CEO Ishita Shah Shares Her Startup Story
- IndependentUnlocking TechBio: How AI is Redefining Market Strategy
- IndependentNorCal AngelCon 2025 Finalist
- IndependentAdvancing Vaginal Health Products, webinar page
- CompanyLaunch HN: Matrubials (YC S21)
- CompanyAntimicrobial Peptides for Treatment and Prevention of BV and other STIs, deck
- CompanyMatrubials website: home, founders, women’s health, updates
- CompanyMatrubials profile and founder bios
- DatabaseMatrubials profiles: funding, investors, patent activity
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
